Effect of F2695 on Functional Recovery After Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.

Also called NCT01639014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 532 participants (enrolled count) (from the registry)
Sponsor
Pierre Fabre Medicament (from the registry)
Registry
  • NCT NCT01639014
  • EudraCT 2012-001592-37
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Czechia, France, Germany, Hungary, Italy, Portugal, Russia, Spain, Sweden, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01639014. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of F2695 on Functional Recovery After Ischemic Stroke
Acronym
LIFE
Intervention (Drug)
F2695
Intervention (Drug)
placebo
Lead sponsor
Pierre Fabre Medicament (class: industry)

Record details

Record id
cardio:ct-nct01639014
Content hash
6a3dd3c6086072c7a612391d345b6be30cd27f4ca625f8dc508898c8adef0fa4